ModiQuant Technology Innovative assessment of modified proteins. Massimo Papale CEO & Co-Founder

Transcription

1 ModiQuant Technology Innovative assessment of modified proteins Massimo Papale CEO & Co-Founder

2 Our Milestones January 2016 Patent application for R/pR test June 2016 Keep Calm & Startup Foggia Prize October prize Heroes 2017 Establishment March 2016 July 2016 September 2017 Operative Unit Social Innovation award Patent application for ModiQuant Technology

3 The Problem Cancer is the second cause of death in the world Tumor markers are poor sensitive and not specific Diagnostic exams are invasive and expensive Late diagnosis 8.7 M * Deaths 17.5 M * New cases M ** New cases 2030 *Global Burden of Disease project WHO **International Agency for Research on Cancer (IARC)

4 New perspectives in cancer diagnostics FLUIDIA S GOAL Variable Diagnostic Power Breast Cancer: 70% Lung cancer : < 30% Increased diagnostic and prognostic power Adapted from : JSM Biotechnol Bioeng (2017)

5 ModiQuant approach A new replicable and scalable method based on the use of recombinant hybrid peptides that is And useful for Setup of IVDs test Quantitative analysis of intracellular signalling Characterization of drugs targets

6 Our First product: The R-pR test The R/pR test: a miniaturizable sandwich immunoassay specifically designed to assess quantitatively and in parallel both native and phosphorylated form of Raf Kinase Inhibitor Protein (RKIP)

7 Our First product: The R-pR test POTENTIAL APPLICATIONS Early diagnosis and prognosis of specific cancer types in more than 500 M patients at risk Urine Breast biopsy Breast Cancer Renal Cancer Faeces EBC Colon Cancer Lung Cancer

8 Source : Kalorama analytics 2016 The Market Total IVDs market 78 Billions $ Total Addressable Market (TAM) 21 M$ (0.26%) -GO to MARKET- On-line selling R/pR test IVDs market (Cancer) 8 Billions $ Distributors Hospitals / Pharmacies

9 Timeline R&D Production & Selling R/pR test optimization Clinical trials POCT development Patent extension Marketing Screening patients Screening patients Screening patients

10 Team & Partnership R&D Massimo Papale, Biologist, PhD CEO & Co-Founder Elena Ranieri, Biologist, PhD Co-Founder Project Management Social Media Marketing V. Mezzolla Biologist A. Giusto R. Quitadamo F. Pesce, Nephrologist Bioinformatics E. Montemurno, Biologist G. Lucarelli, Urologist F. Vincenti, Product designer & Enterpreuner

11 DIAGNOSIS Competitors & drivers of Competitive Advantage Unique non-invasive test for diagnosis and prognosis of kidney cancer Patent pending scalable technology for the quantitative assessment of PTM biomarkers PROGNOSIS ModiQuant Technology may allow the development of a new generation of point of care testing (POCT)

12 Competitive strategy and differentiation BROAD Competitive Scope NARROW COST LEADERSHIP COST FOCUS LOWER COST DIFFERENTIATION DIFFERENTIATION FOCUS DIFFERENTIATION COMPETITIVE ADVANTAGE

13 BUSINESS MODEL KEY PARTNERS Hospitals and Clinical centers for clinical validation Scientific Societis Technological partners (SME and Research Centers) for R&D Consultants for legal aspects and IPR KEY ACTIVITIES Clinical Validation of the R/pR test (ELISA Multipelex) Setup of the Point of Care testing (POCT) for autodiagnosis Scouting new biomarkers and setup new IVD test Customdevelopment of new IVD test Production/sale KEY RESOURCES Patents & Know-how; Managerial Board (CE0;CTO;CSM;CIO) Project managers Social media managers /SEO/SEM Biologists and Lab technicians Clinicians Product specialsists VALUE PROPOSITION R/pR Test; Long-term research experience for constant product innovation; Core network with clinic and research units to speed up clinical validation and technical improvements; Scalability and replicability of ModiQuant technology for the setup of IVDs tests for laboratory (ELISA Multiplex) or for auto-diagnostic (POCT ) purposes; CUSTOMERS RELATIONSHIPS Social media Communication Dedicated Personal assistance Co-creation CHANNELS Direct sales Direct sales through distributors On-line vendors Direct on-line sales CUSTOMERS Public and private laboratories Hospitals Universities Pharmacies Cancer Patients Pre-cancer patients Big-Pharma Biotech SME COSTS Personnel Disposables Intellectual Property Rights Marketing and Social media Communication Logistics Royalties Consultants (legal and business aspects) REVENUES Sales of IVD tests (ELISA assays and POCT) Patents licensing Customized development of new test for R&D and IVD use Projects grants

14 Financial forecasts Cash Flow Fatturato EBITDA EBIT ( ) Return on investment (ROI) Funding GAP CAGR= 31,95% R/pR test optimization Clinical trials POCT development Patent extension Marketing

15 New cases Social Impact Italy + 12 % $/year/patient (> 8 billion $/year) Test R-pR EARLY DIAGNOSIS Drastic reduction in the cost of patient management Better quality of life Breakaway Study (The global burden of cancer- challenges and opportunities, The Economist, 2009)

16 fluidiabiotech.com